We report here that the new liver-de-targeted TGFβ signaling inhibiting adenovirus: mHAdLyp.sT is safe to be used in the TNBC tumor-bearing immunocompetent mouse model and retains its tumor tropism while applied systemically. Here, TGFB1 is linked to neoplasm.